The preclinical activity of ISB 1442, a human anti-CD38 and anti-CD47 bispecific antibody currently in a Phase 1/2 clinical trial for r/r MM (NCT05427812), was evaluated in AML and T-ALL [144]. This evidence concerns the gene CD47 and acute lymphoblastic leukemia.